These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 9852630

  • 1. Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo.
    Beham AW, Sarkiss M, Brisbay S, Tu SM, von Eschenbach AC, McDonnell TJ.
    Int J Mol Med; 1998 Jun; 1(6):953-9. PubMed ID: 9852630
    [Abstract] [Full Text] [Related]

  • 2. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
    Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ.
    Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
    [Abstract] [Full Text] [Related]

  • 3. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
    Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME.
    Int J Cancer; 2001 Mar 15; 91(6):846-50. PubMed ID: 11275990
    [Abstract] [Full Text] [Related]

  • 4. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R.
    Cancer Res; 1995 Oct 01; 55(19):4438-45. PubMed ID: 7671257
    [Abstract] [Full Text] [Related]

  • 5. Effect of Bcl-2 overexpression in human prostate cancer cells in vitro and in vivo.
    Kajiwara T, Takeuchi T, Ueki T, Moriyama N, Ueki K, Kakizoe T, Kawabe K.
    Int J Urol; 1999 Oct 01; 6(10):520-5. PubMed ID: 10533903
    [Abstract] [Full Text] [Related]

  • 6. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
    Fraizer G, Leahy R, Priyadarshini S, Graham K, Delacerda J, Diaz M.
    Int J Oncol; 2004 Mar 01; 24(3):461-71. PubMed ID: 14767530
    [Abstract] [Full Text] [Related]

  • 7. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J.
    Clin Cancer Res; 1999 Oct 01; 5(10):2891-8. PubMed ID: 10537358
    [Abstract] [Full Text] [Related]

  • 8. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
    Drew L, Fine RL, Do TN, Douglas GP, Petrylak DP.
    Clin Cancer Res; 2002 Dec 01; 8(12):3922-32. PubMed ID: 12473608
    [Abstract] [Full Text] [Related]

  • 9. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
    Lowe SL, Rubinchik S, Honda T, McDonnell TJ, Dong JY, Norris JS.
    Gene Ther; 2001 Sep 01; 8(18):1363-71. PubMed ID: 11571575
    [Abstract] [Full Text] [Related]

  • 10. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
    Nesslinger NJ, Shi XB, deVere White RW.
    Cancer Res; 2003 May 01; 63(9):2228-33. PubMed ID: 12727844
    [Abstract] [Full Text] [Related]

  • 11. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW, Lau KW, Tam PC, Shiu SY.
    Prostate; 2002 Jul 01; 52(2):106-22. PubMed ID: 12111702
    [Abstract] [Full Text] [Related]

  • 12. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ.
    Cancer Res; 2004 Aug 01; 64(15):5489-95. PubMed ID: 15289359
    [Abstract] [Full Text] [Related]

  • 13. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.
    Prostate; 2003 Mar 01; 54(4):249-57. PubMed ID: 12539223
    [Abstract] [Full Text] [Related]

  • 14. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer.
    Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordoñez NG, Troncoso P, Navone NM.
    Clin Cancer Res; 2002 Mar 01; 8(3):775-81. PubMed ID: 11895908
    [Abstract] [Full Text] [Related]

  • 15. Induction of apoptosis in BCL-2-expressing rat prostate cancer cells using the Semliki Forest virus vector.
    Murphy AM, Sheahan BJ, Atkins GJ.
    Int J Cancer; 2001 Nov 01; 94(4):572-8. PubMed ID: 11745446
    [Abstract] [Full Text] [Related]

  • 16. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors.
    Westin P, Stattin P, Damber JE, Bergh A.
    Am J Pathol; 1995 Jun 01; 146(6):1368-75. PubMed ID: 7778676
    [Abstract] [Full Text] [Related]

  • 17. PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway.
    Zhang D, He D, Xue Y, Wang R, Wu K, Xie H, Zeng J, Wang X, Zhau HE, Chung LW, Chang LS, Li L.
    Cancer Res; 2011 Mar 15; 71(6):2193-202. PubMed ID: 21385902
    [Abstract] [Full Text] [Related]

  • 18. Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation.
    Johnson MI, Robinson MC, Marsh C, Robson CN, Neal DE, Hamdy FC.
    Prostate; 1998 Dec 01; 37(4):223-9. PubMed ID: 9831218
    [Abstract] [Full Text] [Related]

  • 19. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.
    Mu Z, Hachem P, Hensley H, Stoyanova R, Kwon HW, Hanlon AL, Agrawal S, Pollack A.
    Prostate; 2008 May 01; 68(6):599-609. PubMed ID: 18196567
    [Abstract] [Full Text] [Related]

  • 20. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage.
    Lin Y, Fukuchi J, Hiipakka RA, Kokontis JM, Xiang J.
    Cell Res; 2007 Jun 01; 17(6):531-6. PubMed ID: 17404601
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.